Naturally circulating dendritic cells to vaccinate cancer patients

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Bol, Kalijn F ^a,b   Tel, Jurjen ^a   de Vries, I Jolanda M ^a,b   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer immunotherapy; Dendritic cell targeting; Dendritic cell vaccination; Myeloid dendritic cells; Plasmacytoid dendritic cells

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; DENDRITIC CELL VACCINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CLINICAL STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; MELANOMA; MONOCYTE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 84886943568     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23431     Document Type: Article

References (10)

1. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127.
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258.
3. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106:259-62; PMID:11509173; http://dx.doi.org/10.1016/S0092-8674(01)00456-1.
4. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Lambeck AJ, et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T-cells, despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2012; In press. PMID:23212525; http://dx.doi.org/10.1182/blood-2012-06-435644.
5. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 2012; 120:3936-44; PMID:22966165; http://dx.doi.org/10.1182/blood-2012-06-435941.
6. de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol 2011; 48:810-7; PMID:21257206; http://dx.doi.org/10.1016/j.molimm.2010.12.022.
7. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen specific T cell responses and enhance overall survival in melanoma patients. Cancer Res, In press.
8. Celli S, Day M, Müller AJ, Molina-Paris C, Lythe G, Bousso P. How many dendritic cells are required to initiate a T-cell response? Blood 2012; 120:3945-8; PMID:22995897; http://dx.doi.org/10.1182/blood-2012-01-408260.
9. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 2011; 23:12-20; PMID:21269839; http://dx.doi.org/10.1016/j.smim.2011.01.001.
10. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.org/10.1182/blood-2011-07-3676151.